IP strategyPortfolio planningProtection choices

IP strategy: matching protection to the business

By Ipiry TeamPublished August 30, 20267 min read

Short answer

An IP strategy answers four questions: what to protect, by which right, where, and for how long. The common failure is filing reflexively — patenting everything patentable rather than what matters commercially. A good strategy also decides what not to protect, since holding a patent nobody practises costs up to $14,470 in US fees alone across its life.

An IP strategy answers four questions: what to protect, by which right, where, and for how long.

The commonest failure is filing reflexively — patenting everything patentable rather than what matters commercially.

That produces portfolios where most assets are never practised, each carrying renewal costs and each demanding three decisions across its life.

A real strategy also decides what not to protect, which is the part usually missing.

The four questions

Question	Decides
What to protect	Which inventions and assets
By which right	Patent, design, trademark, copyright, secret
Where	Jurisdictions
For how long	Which to renew, which to release

The fourth is the one nobody plans. It arrives three times per patent and is usually answered by default.

Matching the right to the asset

Asset	Right	Duration
How it works	Utility patent	20 yrs from filing, three fees
How it looks	Design patent	15 yrs from grant, no fees
The name	Trademark	Indefinite with renewal
Code, manuals, content	Copyright	Long
Undetectable processes	Trade secret	Indefinite while secret
Customer relationships	Contracts	As agreed

Most products need several, running on different clocks with different failure modes.

The trademark frequently outlasts everything else. Twenty years after a patent lapses, competitors can make the product and still cannot call it by your name.

The patent-or-secret fork

Consider	Patent	Trade secret
Detectable from the product?	Patent	Secret if not
Would you detect infringement?	Necessary for a patent to matter	—
Independent invention by others	Patent protects	Secret does not
Cost	$8,000–$20,000 + fees	Security measures
Publishes	At 18 months, permanently	Never
Duration	20 years	Indefinite

Filing forecloses secrecy permanently. The application publishes whether or not it grants, and abandoning does not restore it.

A process running inside your own factory is frequently undetectable, which makes enforcement of a patent on it difficult and secrecy the stronger route. See patent application publication.

Where to file

Ask	Why
Where will we sell?	Revenue justifies cost
Where do competitors manufacture?	Reaches the supply chain
Where would we actually enforce?	Practical reality
What is the annuity curve?	Foreign renewals escalate annually
Is the market growing?	Forward view

Manufacturing coverage is undervalued. A patent where a product is made can stop production rather than chasing distribution.

Importation is the fallback. A US patent reaches goods made abroad at the border, which is the answer where local filing is not affordable. See international patent law.

Freedom to operate belongs in the strategy

	Owning patents	Freedom to operate
Question	Can we stop others?	Can we sell?
Analysis	Your claims	Other people's claims
A patent answers it	No	—
When needed	—	Before launch

"We have a patent" is not an FTO answer, and investors know it. The two are separate analyses and both belong in the plan. See fto meaning.

Strategy by stage

Stage	Emphasis
Pre-revenue startup	Core filings, clean assignments, FTO before launch
Growing company	Depth through continuations, key markets
Established	Portfolio segmentation, pruning, licensing
Declining product line	Sell or release deliberately

Startups need depth on the core, not breadth. A small number of well-drafted filings covering what the company actually does answers diligence better than a wide thin portfolio.

Clean contractor and founder assignments matter more than filing count at that stage, because a defect there stops a funding round. See ip due diligence.

Common strategy failures

Failure	Consequence
Filing reflexively	Portfolio of unpractised assets
No FTO analysis before launch	Redesign after tooling
Filing everywhere	Escalating annuities on unused rights
Legal disconnected from product	Protecting the wrong things
No decision at fee windows	Payment by default
Never releasing anything	Cost compounds

Filing reflexively is the expensive one, because each filing commits three renewal decisions and up to $14,470 in US fees before any foreign cost.

Segmenting what you hold

Segment	Test	Strategy
Core	Practised, enforced or blocking	Keep, mark, monitor
Defensive	Covers what a specific opponent does	Keep while relevant
Licensed	Income above cost	Keep, audit
Dormant	Nobody practises the claims	Sell or release
Legacy	Covers a discontinued product	Sell or release

Dormant is the largest segment in most portfolios and the least examined, because nothing about it demands attention until a fee falls due.

Test defensive rationales against a named opponent. Applied portfolio-wide without one, they justify holding everything forever.

What holding costs

Fee	Due after grant	Large	Small	Micro
First	3.5 years	$2,150	$860	$430
Second	7.5 years	$4,040	$1,616	$808
Third	11.5 years	$8,280	$3,312	$1,656
Total per US patent		$14,470	$5,788	$2,894

Foreign annuities add more, annually and escalating. A four-country family generates roughly twenty deadlines a year.

Ipiry Patent Survival Curve v1.0	Rate
Survive the 3.5-year fee (2022 cohort)	85.8%
Survive the 7.5-year fee (2018 cohort)	64.6%
Reach full term (2014 cohort)	41.4%
Abandoned before full term	58.6%
Conditional: paid first two, pay third	63.0%

Computed from 27,273,654 USPTO maintenance fee records covering 8,262,336 US utility patents — see the patent survival curve.

Portfolios shrink by design. The conditional figure is the sharper one: of patents already funded through two windows, more than a third are still released at the third.

Deciding not to protect

Route	Fits when
Defensive publication	You only need to stop others patenting it
Trade secret	Undetectable process
Nothing	Not commercially relevant
Release at a fee window	Value no longer justifies cost

Defensive publication is cheap and underused. It prevents anyone else obtaining a patent, takes effect immediately, and costs a fraction of filing.

Releasing is a decision, not a failure. The failure is releasing by inattention when the asset could have been sold first. See patent monetization strategies.

The annual review

Step	Timing
1. List every fee due in the next 18 months	Q1
2. Verify entity status and recalculate	Same
3. Screen for products practising each patent	Free
4. Segment: core, defensive, licensed, dormant	Same
5. Start any sale process	Immediately for dormant assets
6. Diarise each window as a decision	Not a payment

Eighteen months of lookahead is what keeps selling possible. A review in the final month leaves paying or lapsing.

Phrase calendar entries as decisions. "Pay $3,312" produces a payment; "decide: keep, sell, license or release" produces a decision.

Who owns it

Owner	Why
Commercial authority, advised by counsel	These are spending decisions
Legal alone	Disconnects from the roadmap
Engineering alone	Misses the commercial view
Nobody	The default, and the reason portfolios drift

IP decisions are business decisions. They fail when treated as a purely legal function operating apart from what the company sells.

IP strategy: the checklist

Answer four questions — what, which right, where, how long.
Match the right to the asset. Most products need several.
Decide patent or secret before filing. Filing forecloses secrecy permanently.
File where you sell and where competitors manufacture.
Include freedom to operate explicitly. Owning patents does not answer it.
Prioritise depth on the core over breadth, especially early.
Get clean assignments from every contractor and founder.
Segment the portfolio and test defensive rationales against a named opponent.
Decide what not to protect. Defensive publication is cheap.
Review annually with eighteen months of lookahead, so selling stays possible.

Common questions

What is an IP strategy?

A set of decisions about what intellectual property to protect, by which right, in which countries, and for how long — aligned to what the business actually sells and who it competes with, rather than to what is technically patentable.

What is the most common IP strategy mistake?

Filing reflexively. Patenting everything patentable produces a portfolio of assets nobody practises, each carrying up to $14,470 in US maintenance fees across its life, and each requiring three renewal decisions.

Which right should protect what?

Patents for how things work, design patents for appearance, trademarks for names and brands, copyright for code and content, and trade secrets for undetectable processes. Most products need several, running on different clocks.

Should I patent or keep it secret?

If the invention is undetectable from the product, trade secret has no expiry and no filing cost. Filing forecloses that permanently, because the application publishes at eighteen months whether or not it grants.

Where should I file?

Where you sell and where competitors manufacture. Coverage in a manufacturing jurisdiction reaches the supply chain, which is frequently more useful than coverage in a small sales market. Each country adds annual renewal costs.

How does strategy differ for a startup?

Startups need enough IP to answer investor diligence and enough freedom to operate to launch. That usually means a small number of well-drafted filings covering the core, not breadth, plus clean assignments from every contractor.

What is defensive strategy?

Holding patents that give you something to assert if someone sues you, which changes the economics of an assertion against you. It only works where the claims cover what a likely opponent actually does.

How often should the strategy be reviewed?

Annually, against the next eighteen months of deadlines. That cadence keeps selling possible, since a sale takes months and a patent sold before a fee deadline is worth something while one lapsed afterwards is worth nothing.

Does an IP strategy include what not to file?

It should. Deciding not to protect something is a strategic decision, and defensive publication is a cheap way to stop others patenting it without carrying the cost of a patent yourself.

How much should a business spend on IP?

Enough to protect what generates revenue and to clear the path for what will. Beyond that, spend tends to reflect habit rather than strategy — which shows up as portfolios where most assets are never practised or enforced.

What about freedom to operate?

It belongs in the strategy explicitly. Owning patents says nothing about whether you can sell, because a patent is a right to exclude rather than permission to practise. The two analyses are separate and both are needed.

Who should own the IP strategy?

Someone with commercial authority, advised by counsel. IP decisions are business decisions about where to spend and what to protect, and they fail when treated as a purely legal function disconnected from the product roadmap.

Patent portfolio management: the operating cadence

How to run a patent portfolio operationally — the review cycle, the four-way decision at each fee window, how to rank patents cheaply, and what a defensible budget looks like.

IP portfolio management across all rights

Managing patents, trademarks, copyright and trade secrets as one portfolio — what to record, how the renewal cadences differ, who owns the decisions, and where budgets actually go.

Patent monetization strategies: choosing and sequencing

How to choose between monetization routes — matching strategy to your situation, sequencing routes over a patent's life, and the decision points that close options.

What is your patent worth?

Free AI valuation in 60 seconds, benchmarked against 652,000 KPSS patent value records and the Ipiry Patent Survival Curve.

Value My Patent Free →Takes 60 seconds. No credit card required.